Literatuur
- Hagen P van et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. The New England journal of medicine. 2012; 366(22): 2074-84
- Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England). 2010; 376(9742): 687-97
- Dijksterhuis WPM et al. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study. Int J Cancer. 2019
- Cunningham D et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England journal of medicine. 2008; 358(1): 36-46
- Zweeden AA van et al. Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer. Cancer Chemother Pharmacol. 2018; 82(1): 39-48
- Wilke H et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet Oncology. 2014; 15(11): 1224-35
- Shitara K et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018; 19(11): 1437-48
- Janjigian Y et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastrooesophageal junction and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021
- Sun JM et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, Phase 3 study. Lancet 2021; 398: 759-7
Commissie BOM adviezen
Ga naar de commisie BOM adviezen over oesofaguscarcinoom.
Richtlijnen
Ga naar de richtlijn Oesofaguscarcinoom in de FMS richtlijnendatabase.